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Abstract
A chlorinated withanolide, 6α-chloro-5β,17α-dihydroxywithaferin A (1), and nine known
withanolides, 6α-chloro-5β-hydroxywithaferin A (2), (22R)-5β-formyl-6β,27-dihydroxy-1-oxo-4-
norwith-24-enolide, withaferin A, 2,3-dihydrowithaferin A, 3-methoxy-2,3-dihydrowithaferin A,
2,3-didehydrosomnifericin, withanone, withanoside IV and withanoside X, were isolated from
Withania somnifera (Solanaceae). All structures were elucidated on the basis of spectroscopic
methods (IR, HRESIMS, 1D/2D NMR). X-ray crystallography confirmed the absolute
configuration of 1.
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1. Introduction
Withanolides are a group of naturally occurring C28-steroidal lactones built on an intact or
rearranged ergostane scaffold in which C-22 and C-26 are appropriately oxidized to form a
δ-lactone ring on the nine-carbon side chain. These compounds are mainly found in
members of the plant family Solanaceae (Mirjalili et al., 2009) and are known to possess
various biological activities including anticarcinogenic (Christina et al., 2004), antioxidant
(Bhattacharya et al., 1997), adaptogenic (Dhuley, 2000), antiparkinsonism (Nagashayana et
al., 2000), antibacterial (Arora et al., 2004), anti-inflammatory (Al-Hindawi et al., 1989),
immunomodulatory (Davis and Kuttan, 2000) and antidepressant (Bhattacharya et al., 2000)
effects. As part of our ongoing investigation of antiproliferative withanolides (Samadi et al.,
2010), we selected Withania somnifera L. Dunal as an abundant source of these compounds.
W. somnifera, commonly known as “ashwagandha” and widely cultivated in the drier parts
of India, is well known for its use in Ayurvedic medicine. Previous research supports its
pharmacological uses, confirming antioxidant, anti-inflammatory (Sumantran et al., 2008),
immunomodulatory, anticarcinogenic, antibacterial (Owais et al., 2005), antiparkinsonism
(Sankar et al., 2007) and antistress (Geetha and Harish, 2006) properties. Raw plant material
and extracts of this species are currently sold as dietary supplements in the USA for
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increasing energy and endurance, strengthening immune function, and helping the body
overcome imbalance. More than 130 withanolides have been reported in previous
investigations from the same species. Herein, we report the isolation and structural
elucidation of a new chlorinated withanolide (1), named 6α-chloro-5β,17α-
dihydroxywithaferin A (Fig. 1), along with other nine known withanolides.
2. Results and discussion
The ethyl acetate-soluble fraction of the crude extract acquired for this study was subjected
to repeated column chromatography to yield compound 1. Compound 1 was obtained as
colorless parallelepiped-shaped crystals by recrystallization from MeOH–CH2Cl2–EtOAc
(5:1:1). The molecular formula C28H39ClO7 was deduced from its HRESIMS (observed m/z
523.2440 [M + H]+, calcd for C28H40ClO7 523.2463) and NMR data. The presence of
chlorine was supported by the intensity of the [M + H +2]+ peak, which was approximately
one-third as intense as the pseudomolecular ion peak [M + H]+. IR absorption bands at
3500, 1700, and 1650 cm−1 revealed the presence of OH, carbonyl and lactonic groups.
The 13C NMR (DEPT) spectrum of 1 displayed 28 signals which were assigned to four
methyl, seven methylene (including one oxygenated at δ57.3), nine methine (including two
olefins at δ127.8 and 142.8), and eight quaternary carbons (including one keto carbonyl at
δ200.2 and one ester carbonyl at δ167.0, two olefins at δ154.2 and 125.2, two oxygenated at
δ84.8 and 78.1) corresponding to C28H35. Thus, the remaining four hydrogen atoms were
assigned to four OH groups. These data were consistent with the characteristic features of
withanolides, C28-steroidal lactones with a δ-lactone ring on the nine-carbon side chain.
The 1H NMR spectrum of 1 also showed typical signals for a withanolide. The four methyl
groups resonated at δ0.99 (3H, d, J = 7.0 Hz), δ0.78 (3H, s), δ1.27 (3H, s), and δ2.03 (3H,
s), corresponding to the secondary methyl of C-21 and the quaternary methyls C-18, 19 and
28 of a withanolide.
The NMR data of 1 was very similar to those of another chlorinated withanolide, 6α-
chloro-5β-hydroxywithaferin A 2 (Nittala et al., 1981), isolated during this study. The
obvious difference between 1 and 2 was the presence of a quaternary carbon (δ84.8) in 1 and
a methine carbon (C-17) in the latter (1H NMR δ 1.07, 13C NMR δ51.8), suggesting that 1
was a 17-hydroxy derivative of 2. This observation was supported by the high-frequency
shift of C-13 (δ48.3 in 1 and δ43.2 in 2), C-16 (δ36.5 in 1 and δ27.2 in 2), and C-20 (δ42.6
in 1 and δ38.7 in 2) in the 13C NMR spectra. It was also supported by the 1H-1H COSY and
HSQC spectra (a fragment CH3-CH-CH(O)-CH2- of the side chain linked to the oxygenated
quaternary C-17 in 1 and a fragment CH3-CH-CH(O)-CH2- of the side chain linked to
methine C-17 in 2), and the HMBC correlations (Fig. 2) between H3-21 (δ0.99) and C-17
(δ84.8), between H3-18 (δ0.78) and C-17 (δ84.8) in 1. The full assignments of NMR data
(Table 1) were obtained by 2D NMR including 1H-1H COSY, HSQC and HMBC spectra.
Finally, the structure of 1 was confirmed through single-crystal X-ray diffraction
experiments (Fig. 3). The absolute configuration of 1 was confirmed on the basis of
anomalous scattering of the chlorine atoms in the crystal. Thus, the structure of the new
withanolide 1 was established as 6α-chloro-5β,17α-dihydroxywithaferin A.
The known compounds were identified, by comparison of their NMR and MS data with
those reported in the literature, as 6α-chloro-5β-hydroxywithaferin A (2) (Nittala et al.,
1981); (22R)-5β-formyl-6β,27-dihydroxyl-1-oxo-4-norwith-24-enolide (Nittala and Lavie,
1982); withaferin A, 2,3-dihydrowithaferin A and 3-methoxy-2,3-dihydrowithaferin A
(Pelletier et al., 1979); 2,3-didehydrosomnifericin (Choudhary et al., 1996); withanone
(Gottlieb and Kirson, 1981); withanoside IV (Matsuda et al., 2001) and withanoside X
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(Zhao et al., 2002). Full assignments of NMR data for the known chlorinated withanolide 2
were listed in Table 1 because those values reported in the literature (Nittala et al., 1981)
and, especially the assignments of its 13C NMR data (C-4, 6, 10, 14, 17), need to be revised.
Chlorinated compounds such as 1 and 2 are not commonly encountered in higher plants. To
date, only five other chlorinated withanolides have been reported from W. somnifera,
including withanolide C (Bessalle and Lavie, 1992), withanolide Z (Pramanick et al., 2008),
6α-chloro-5β-hydrowithanolide D, 4-deoxyphysalolactone (Nittala et al., 1981) and 27-
acetoxy-5β-chloro-6α-hydroxywithaferin A (Choudhary et al., 2010). With the exception of
27-acetoxy-5β-chloro-6α-hydroxywithaferin A and withanolide Z, all the reported
chlorinated withanolides contain a 6α-chloro-5β-hydroxy system. This suggests that the
epoxide rings that are usually encountered at C-5 and C-6 have undergone a diaxial opening
(Nittala et al., 1981).
3. Experimental
3.1. General
Optical rotations were obtained on a Rudolph Research Analytical Autopol IV Automatic
polarimeter. Melting points were recorded using a MPA100 OptiMelt Automated Melting
Point System (Stanford Research Systems, Sunnyvale, CA). UV data were acquired using an
Agilent Technologies 1200 HPLC (Diode Array Detector). HPLC was conducted on Agilent
Technologies 1200 series system. IR data were obtained using a Thermo Nicolet Avatar 360
FT-IR instrument. NMR spectra were recorded on either a Bruker DRX-400 with a qnp
probe or on a Bruder AV-500 with a cryoprobe. 1H and 13C spectra were recorded using the
residual protonated signal in the CDCl3 solvent (δH 7.24) or the central peak of the CDCl3
triplet (δC 77.00) as the internal standard. High resolution mass spectrometry data were
collected on a LCT Premier time of flight mass spectrometer (Waters Corp., Milford, MA).
Normal phase TLC was performed on Sorbent Technologies Silica G TLC plates (200 μm,
w/UV 254) using the solvent system CH2Cl2–EtOAc–MeOH (1:8:1), and reverse phase
TLC was performed on Sorbent Technologies C18 TLC plates (150 μm, w/UV 254) using
H2O-MeOH (1:1). Spots were visualized using UV light (254 nm) and spraying with
vanillin-sulfuric acid reagent.
3.2. Plant Material
The plant crude extract was acquired from PhytoMyco Research Corporation, Greenville,
NC in March 2009. The extract was prepared according to published procedures by
sequential extraction of the dried and ground leaves of W. somnifera with a mixture of
CH2Cl2 and MeOH (1:1, v/v) followed by MeOH and H2O to obtain three fractions
(Jayaprakasam and Nair, 2003). All fractions were then combined, filtered and dried under
reduced pressure. The original extract has been stored at -20 °C in our laboratory to serve as
a reference material.
3.3. Extraction and Isolation
The powdered, dried plant extract (189 g) of W. somnifera was dissolved in 200 mL of water
to form a suspension. The mixture was defatted with hexane (2 L × 3), and the aqueous
phase was extracted with EtOAc (2 L × 6) and BuOH (2 L × 3) to obtain 32.9 g of EtOAc
extract and 80.0 g of BuOH extract. The EtOAc extract was then subjected to passage over a
Si gel column (600 g, 32 ∼ 63 μm, Sorbent Technologies), eluted sequentially with CH2Cl2-
CH3COCH3 solvent gradient (0–100%) followed by MeOH, to give eight major fractions
(Fraction A-H). Fraction F was chromatographed on a Si gel (200 g, 12 ∼ 26 μm, Sorbent
Technologies) MPLC column, eluted with CH2Cl2–EtOAc–MeOH (40:10:1), to afford four
further fractions (F1–F4). Fraction F2 was applied onto a C-18 reverse phase column (100 g,
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Sorbent Technologies), eluted with MeOH–H2O (3:7) to remove the green color. The
colorless fraction F2 was then separated on a Sephadex LH-20 column (200 g, GE
Healthcare), eluted with MeOH to obtain the major components, and then purified by
separation over a Si gel column (50 g, 12 ∼ 26 μm, Sorbent Technologies), eluted with
CH2Cl2–MeOH–EtOAc (18:1:1), to yield 1 (5 mg). Fraction F1 was purified on a Sephadex
LH-20 column (200 g, GE Healthcare), eluted with MeOH, to afford 2,3-
didehydrosomnifericin (21 mg). Compound withanone (800 mg) was obtained as fine
needles by recrystallization of fraction D from CHCl3–CH3COCH3 (1:1). Fraction E was
chromatographed on a Si gel column, eluted with CH2Cl2–CH3COCH3 (10:1), to collect
twelve fractions (E1–El2), and E6 was identified as withaferin A (34 mg). The major
withanolide in fraction E7 was obtained as a white powder yielding 3-methoxy-2,3-
dihydrowithaferin A (22 mg) by recystallization from CHCl3–CH3COCH3 (1:1). E12 was
separated over a C-18 reverse phase SPE column (5 g, 20 mL, Phenoment strata C-18),
eluted with MeOH-H2O (1:1), to give a mixture of two compounds. Further purification of
the mixture by HPLC using isocratic elution with CH3CN–H2O (45:55) provided (22R)-5β-
formyl-6β,27-dihydroxy-1-oxo-4-norwith-24-en (1.5 mg) and 2,3-dihydrowithaferin A (1.2
mg). Compound 2 (7.3 mg) was purified from fraction E11 by a C-18 reverse phase SPE
column (5 g, 20 mL, Phenoment strata C-18) using MeOH–H2O (1:1).
The n-BuOH extract was subjected to passage over a Si gel column (2 kg, 12 ∼ 26 μm,
Sorbent Technologies), eluted sequentially with MeOH–CH2Cl2 solvent gradient (30%–
100%), to give 24 fractions. Fraction 4–5 was purified on a Sephadex LH-20 column (200 g,
GE Healthcare), eluted with MeOH–H2O (8:2), to afford a withanoside-rich fraction. This
faction was further purified by PTLC eluting with CH2Cl2–MeOH–H2O (40:10:1) and semi-
prep HPLC eluting with CH3CN–H2O (25:75) to afford withanoside IV (5.6 mg) and
withanoside X (6.3 mg).
3.4 6α-chloro-5β,17α-dihydroxywithaferin A (1)
Colorless crystal (MeOH); mp 238-240 °C; [α]25546 +53.1 (c 0.001, MeOH); UV (MeOH)
λmax (log ε) 220 (3.93) nm; IR (film) νmax 3500, 2980, 1700, 1650, 1630 and 1050 cm-1; 1H
NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) see Table 1; ESIMS m/z 523
[M + H]+; HRESIMS m/z 523.2440 (calc. for C28H40ClO7, 523.2463).
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Key HMBC correlations of compound 1.
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ORTEP view of chlorinated withanolide 1.
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Table 1
1H and 13C NMR data of chlorinated withanolides 1 and 2 in CDCl3.
No. 1 2
1Ha 13Cb 1Ha 13Cb
1 200.2 200.1
2 6.02 dd (10.4, 2.2) 127.8 6.00 dd (10.4, 2.2) 127.8
3 6.50 dd (10.4, 2.5) 142.8 6.47 dd (10.4, 2.5) 142.8
4 5.06 br s 66.1 5.01 br s 66.2
5 78.1 78.1
6 4.45 dd (12.7,4.6) 66.5 4.42 dd (12.5,4.9) 66.7
7 2.30; 1.71 39.3 2.30; 1.63 39.4
8 1.63 35.2 1.62 35.1
9 1.27 45.3 1.27 45.8
10 57.1 57.2
11 1.33; 0.97 22.4 1.33; 0.90 22.7
12 1.58; 1.31 31.6 1.89; 1.04 39.0
13 48.3 43.2
14 1.64 49.6 1.05 55.3
15 1.71; 1.21 23.3 1.63; 1.18 24.0
16 1.97; 1.68 36.5 1.67; 1.37 27.2
17 84.8 1.07 51.8
18 0.78 s 14.8 0.65 s 11.8
19 1.27 s 9.9 1.24 s 9.9
20 2.26 42.6 1.87 38.7
21 0.99 d (7.0) 9.4 0.95 d (7.0) 13.3
22 4.65 m 78.9 4.38 m 78.6




27 4.39 d (12.6); 4.35 d (12.6) 57.3 4.37 d (12.6); 4.33 d (12.6) 57.4
28 2.03 s 20.0 2.00 s 20.0
a
δ(ppm) 500 MHz; multiplicities; J values (Hz) in parentheses.
b
δ(ppm) 125 MHz.
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